Ailawadhi S et al. Isatuximab subcutaneous by on-body injector versus isatuximab intravenous plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Phase III IRAKLIA study. J Clin Oncol 2025;[Online ahead of print]. Abstract
Badros A et al. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: The AURIGA study. Blood 2025;145(3):300-10. Abstract
Callander NS et al. Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk. Blood Cancer J 2024;14(1):69. Abstract
Dimopoulos MA et al. Daratumumab (DARA)/bortezomib/lenalidomide/dexamethasone (D‐VRd) with D‐R maintenance (maint) in transplant‐eligble (TE) newly diagnosed myeloma (NDMM): PERSEUS cytogenetic risk analysis. IMS 2024;Abstract OA-48.
Dimopoulos MA et al. Daratumumab or active monitoring for high-risk smoldering multiple myeloma. N Engl J Med 2024;392(18):1777-88. Abstract
Dimopoulos MA et al. Phase 3 randomized study of daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Primary results of the AQUILA study. ASH 2024;Abstract 773.
Facon T et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. New Engl J Med 2024;391:1597-609. Abstract
Facon T et al. Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa‐VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ). IMS 2024;Abstract OA-49.
Foster L et al. Daratumumab plus lenalidomide (D-R) versus lenalidomide (R) alone as maintenance therapy in newly diagnosed multiple myeloma (NDMM) after transplant: Analysis of the phase 3 AURIGA study among clinically relevant subgroups. ASH 2024;Abstract 675.
Gay F et al. Analysis of sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III ISKIA trial). EHA 2025;Abstract S208.
Gay F et al. Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial). ASCO 2025;Abstract 7502.
Leleu X et al. Isatuximab subcutaneous via an on-body delivery system versus isatuximab intravenous, plus pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma: The randomized phase 3 IRAKLIA study. EHA 2025;Abstract S203.
Leleu X et al. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: The randomized phase 3 BENEFIT trial. Nat Med 2024;30:2235-41. Abstract
Mai EK et al. Impact of minimal residual disease on progression-free survival in patients with newly diagnosed multiple myeloma treated with isatuximab, lenalidomide, bortezomib and dexamethasone induction therapy in the phase 3 GMMG-HD7 trial. ASH 2024;Abstract 364.
Moreau P et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: Long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. Lancet Oncol 2024;25(8):1003-14. Abstract
Moreau P et al. Daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTD) followed by DARA maintenance in transplant-eligible (TE) newly diagnosed multiple MYELOMA (NDMM): >6-year update of CASSIOPEIA. EHA 2024;Abstract S204.
Perrot A et al. Minimal residual disease-driven strategy following isatuximab-carfilzomib-lenalidomide-dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma: Primary endpoints of the phase 3 MIDAS trial. EHA 2025;Abstract S205.
Perrot A et al. MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trial. ASCO 2025;Abstract 7500.
Sonneveld P et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. New Engl J Med 2024;390:132-47. Abstract
Usmani SZ et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: The randomized phase 3 CEPHEUS trial. Nature Med 2025;31(4):1195-202. Abstract
Voorhees PM et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): Final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol 2023;10:e825-37. Abstract